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Background: Mesenchymal stem cells (MSC) are in clinical trials for widespread indications including
musculoskeletal, neurological, cardiac and haematological disorders. Furthermore, MSC can ameliorate pulmonary
fibrosis in animal models although mechanisms of action remain unclear. One emerging concept is that MSCs may
have paracrine, rather than a functional, roles in lung injury repair and regeneration.
Methods: To investigate the paracrine role of human MSC (hMSC) on pulmonary epithelial repair, hMSC-
conditioned media (CM) and a selected cohort of hMSC-secretory proteins (identified by LC-MS/MS mass
spectrometry) were tested on human type II alveolar epithelial cell line A549 cells (AEC) and primary human small
airway epithelial cells (SAEC) using an in vitro scratch wound repair model. A 3D direct-contact wound repair model
was further developed to assess the migratory properties of hMSC.
Results: We demonstrate that MSC-CM facilitates AEC and SAEC wound repair in serum-dependent and –
independent manners respectively via stimulation of cell migration. We also show that the hMSC secretome
contains an array of proteins including Fibronectin, Lumican, Periostin, and IGFBP-7; each capable of influencing
AEC and SAEC migration and wound repair stimulation. In addition, hMSC also show a strong migratory response
to AEC injury as, supported by the observation of rapid and effective AEC wound gap closure by hMSC in the 3D
model.
Conclusion: These findings support the notion for clinical application of hMSCs and/or their secretory factors as a
pharmacoregenerative modality for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung
disorders.
Keywords: Mesenchymal stem cells, Idiopathic pulmonary fibrosis, Alveolar epithelial wound repair, MSC secretory
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Bone marrow-derived mesenchymal stem cells are a popu-
lation of multipotent adult stem cells, distinct from haem-
atopoietic stem cells, that classically can differentiate into
mesodermal lineages including osteoblasts, chondrocytes,
adipocytes, and cardiomyocytes [1-3]. Numerous reports
also suggest differentiation into other, non-mesodermal
lineages including neurons [4,5], hepatocytes [6] and lung
epithelial cells [7-9].* Correspondence: n.r.forsyth@keele.ac.uk
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reproduction in any medium, provided the orThis evidence provides a strong rational for the poten-
tial application of hMSCs in regenerative therapeutic
approaches in many diseases including those of the lung
where effective treatment options may be limited [10].
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive fibrotic lung disorder of unknown aetiology and the
most common and lethal form of interstitial lung diseases
with a post diagnosis median survival time of 3–5 years
irrespective of its treatment status [11]. Hypothetically,
the pathophysiology of IPF is most likely associated with
multiple alveolar injuries, failure or delayed alveolar
reepithelialisation, abnormal immune responses and sub-
sequent fibrosis [12-14]. Studies involving the bleomycin-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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animal model of pulmonary fibrosis [15], demonstrated
the migration and homing of endotracheal or systematic-
ally transplanted MSCs towards the site of injury and at-
tenuation of pulmonary fibrosis [16,17]. However, the
magnitude of the amelioration of fibrosis appeared out of
proportion to the numbers of engrafted MSCs which had
differentiated into alveolar epithelial cells (AECs) indicat-
ing the involvement of other mechanisms in this MSC-
mediated reparative process. An emerging consensus is
that paracrine mechanisms could be associated with
MSC-mediated wound repair and tissue regenerative
process [18]. However, the identity of these paracrine
factors with a putative role in alveolar injury repair and re-
generation is not clear.
A wide range of different growth factors, cytokines
and extracellular matrix proteins (ECM) have been
identified as constituents of the in vitro cultured MSC
secretome [19,20]. Many of these secretory proteins are
biologically active with anti-inflammatory, anti-fibrotic
and immunomodulatory functions [21,22]. Previous
reports have demonstrated that conditioned media ob-
tained from MSC culture improved cutaneous wound
healing [19,23] and cardiac repair [24]. However, data
supporting the role of MSC-secreted paracrine factors in
the mediation of AEC wound repair is absent. In this
study, we have tested hMSC serum-free conditioned
media (CM) on AEC wound repair using an in vitro
scratch wound repair assay. We demonstrate that hMSC-
CM alone increased AEC migration, contained an array of
secretory proteins, but had little impact on the rate of
wound repair. However, supplementation of hMSC-CM
with trace levels of serum (0.2%) significantly increased
both migration and wound repair. A selected cohort of
hMSC secretory proteins were tested for their effect on re-
pair of AEC and small airway epithelial cells (SAEC)
isolated from small airways of distal human lung, and di-
verse effects on wound healing and cell migration were
noted. By developing a direct contact co-culture wound
repair system we also demonstrated that when placed in
close proximity, hMSCs would migrate into, and repair,
AEC wounds in vitro. These findings provide an insight in
understanding the cellular and paracrine effects of hMSC
in alveolar wound repair and for possible application of
hMSC secretory products or their equivalent recombinant
proteins as an alternative pharmacoregenerative thera-
peutic option for pulmonary fibrosis.
Methods
hMSC isolation and cell culture
hMSCs were isolated and expanded from human bone
marrow aspirates following previously published meth-
odology [25,26]. Briefly, human whole bone marrow as-
pirate (collected from iliac crest) (Lonza, USA) wasseeded at a density of 105 mononuclear cells/cm2 on
10 ng/ml Fibronectin-coated (Cat. No. F0895, Sigma)
T-75 tissue culture flasks in 20 ml of DMEM (High glu-
cose, 4.5g/L) supplemented with 5% foetal bovine
serum (FBS), 1% L-glutamine, 1% non-essential amino
acid (NEAA) and 1% PSA (Penicillin-Streptomycin-
Amphotericin B) without any prior gradient centrifu-
gation or immunoselection. Cells were maintained in
continuous culture for three weeks in a humidified incu-
bator at 37°C in the presence of 5% CO2 and 95% air.
After 7 days, half of media was removed and replaced with
antibiotic-free medium as described above. Media was
replenished after a further week. At the end of third week,
the adherent hMSC population was harvested with trypsin
and passaged subsequently using 1:4 split ratio for expan-
sion. Passage 1 to 3 cells and their conditioned media were
used for all experiments. Human type II alveolar epithelial
cell (AEC) line, A549 cells were purchased from ATCC,
Rockville, USA and maintained in a continuous culture in
DMEM supplemented with 10% FBS, 1% L-glutamine and
1% NEAA and passage 10–45 cells were utilised for
wound repair and migration assay. Human primary small
airway epithelial cells (SAEC) were purchased from Lonza,
USA and cultured following manufacturer instruction
using SAGM Bullet Kit (Lonza, USA) complete growth
media. SAECs were harvested and passaged using Subcul-
ture Reagent Pack (Lonza, USA). Passage 3 to 4 SAECs
were used for all experiments. Human normal lung fibro-
blast cell line CCD-8Lu was purchased from ATCC,
Rockville, USA and maintained in a continuous culture
(passage 9–14) in DMEM supplemented with 10% FBS,
1% L-glutamine and 1% NEAA. This research did not in-
volve human participants. All cells used in this study were
obtained from commercial third party organizations.
Characterisation of hMSCs and AECs
MSCs (passage 1) were plated on 24-well plates and
grown to 80-90% confluency for immunophenotyping.
Cells were fixed with 4% paraformaldehyde, blocked with
3% BSA (Bovine serum albumin), and characterised using
the human MSC characterisation kit containing anti-
human mouse anti-CD44, anti-CD90, anti-CD146, anti-
CD14, anti-CD19 and anti-STRO-1 primary antibodies at
1:500 dilution (Cat. No. SCR067, Millipore). Cells were
incubated with primary antibodies at 4°C overnight. Sec-
ondary antibodies were anti-mouse IgG-NL557 for all ex-
cept STRO-1 and anti-mouse IgM-NL493 for STRO-1
(both at 1:200 dilutions) (R & D System). For functional
characterisation, isolated hMSCs were differentiated into
osteogenesis, adipogenesis and chondrogenesis lineages
using StemProW hMSC differentiation kits following the
manufacturer’s instructions (Gibco, Invitrogen, USA).
Briefly, for osteogenesis and adipogenesis, 2 × 104 hMSCs
(passage 1) were seeded into each well of 24-well plates
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complete MSC culture media as described above. Cells
were then cultured for three weeks in StemProW Osteo-
genic (Cat. No- A10072-01) and StemProW Adipogenic
(Cat. No- A10070-01) differentiation media with media
changes every two days. For chondrogenesis, the micro-
mass culture system was used according to the manu-
facturer’s instructions. Briefly, 8 × 104 hMSCs (passage 1)
were resuspended in 7 μl of complete media and dropped
at the centre of a 24-well plate as a micromass and
cultured for 2 hours in a humidified incubator in standard
culture condition allowing them to adhere with the cul-
ture surface. Micromasses were then replenished with
StemProW Chondrogenic differentiation media (Cat. No-
A10071-01) and cultured for three weeks in standard
culture conditions with media change every two days.
Osteogenesis, adipogenesis and chondrogenesis were
confirmed by traditional validated cytological staining
with Alizarin Red, Oil Red O and Alcian Blue as well as
by immunostaining with anti-osteocalcin, anti-FABP-4
and anti-aggrecan antibodies respectively following
manufacturer’s protocol (Human MSC Functional Identi-
fication Kit, Cat. No- SC006, R & D System). For visual-
isation, secondary antibodies were used; anti-mouse IgG-
NL557 for osteocalcin and anti-goat IgG-NL493 for FABP-
4 and aggrecan (both at 1:200 dilutions) (NorthernLights, R
& D System). AEC line A549 cells were immunostained
with rabbit anti-proSP-C primary antibody (polyclonal,
ab40879, Abcam), a specific marker for type II AEC, at
1:250 dilution and FITC-conjugated anti-rabbit secondary
was used at 1:200 dilution for visualisation (Abcam). DAPI
was used for nuclear staining in all immunocytochemistry
assays. Images were acquired by a fluorescent microscope
(Nikon Eclipse Ti-ST, Japan) (Figure 1).
In vitro AEC and SAEC wound repair assay
The in vitro wound repair assay was performed following
the protocol described elsewhere [27]. Briefly, AECs and
SAEC were cultured to confluence as monolayers on
48-well plates in complete growth media (10% FBS
supplemented DMEM for AEC and complete SAGM for
SAEC) under standard culture condition. Linear scratch
wounds were made on cell monolayers with plastic pipette
tips and cell debris were removed by washing with PBS
and SF-basal media. Wounded monolayers were then
replenished with either serum-free DMEM (SF-DMEM)
for AEC and SF-SABM (basal media) for SAEC as nega-
tive control, 10% FBS supplemented DMEM for AEC and
complete SAGM for SAEC as positive control, serum-free
MSC conditioned media (SF-MSC CMDMEM (for AEC)
or SF-MSC CMSABM (for SAEC)) or SF-MSC CMDMEM
supplemented with different concentrations of FBS for 24
hours (Figure 2A, 2B, 2C and 2D). Wound images were
recorded with a digital camera (Canon) attached to aninverted light microscope (Nikon Eclipse, TS100) at 0 and
24 hours (Figure 2C and 2D). Circumferential wound gaps
were measured by Image J software (NIH, USA) and per-
centage of wound repair after 24 hours was calculated. For
preparation of MSC-CM, hMSCs (passage 1–3) were
grown to 80-90% confluency in T75 tissue culture flasks
using 5% FBS supplemented complete MSC culture
media. Cells were washed once with PBS and twice with
SF-DMEM (or SABM for SAEC) to remove any serum.
hMSCs were conditioned by exposing SF-DMEM (for
testing on AEC) and SF-SABM (for testing on SAEC) (160
μL/cm2) on 80-90% confluent MSCs (8.2 ± 1.2 × 105 cells/
flask) for 24 hours in standard culture condition. SF-MSC
CMDMEM and SF-MSC CMSABM were collected, centri-
fuged to remove any cell debris and stored at -80°C and
sterile filtered prior to use. Serum-free conditioned media
was obtained from 80-90% confluent CCD-8Lu cells by
exposing SF-DMEM (160 μL/cm2) for 24 hours and
stored as described above. In vitro wound repair assay on
AEC with CCD-8Lu CM (conditioned media) was
replicated as performed using MSC CM described above
(Figure 3A, 3C). Serum was added to all CM, as indicated,
immediately prior to use. All media was conditioned in a
serum-free state.
Internuclear distances between migrated AECs and the
cells attached to the wound margins were measured by
Image J software. A total 108 measurements were recorded
from six individual experiments (Figure 2E and 2F).
MTT assay
To evaluate the effects of MSC-CM and CCD-8Lu CM on
AEC proliferation during wound repair, we have per-
formed a set of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay using MTT reagent
Thiazolyl Blue Tetrazolium Bromide (Sigma, Cat No-
M5655) following manufacturer instructions [28]. Briefly,
105 AEC were grown confluence on each well of 48-well
plate in 24 hours and wounds were made as described
earlier. For 0 hour reading, MTT was performed just after
wounding. Wounded monolayers were washed and 300 μl
of 0.5 mg/ml MTT reagent containing SF-DMEM solu-
tion was added in each well and incubated at 37°C for 2
hours. After incubation, MTT solution was discarded and
washed twice with pre-heated PBS. The formazan was
then extracted by 100% DMSO (250 μl/well) incubating
10 minutes in the incubator. 200 μl of extracted
formazan-DMSO solution was then loaded in each well of
96-well plate and absorption was measured by micro-plate
reader (BioTek, Synergy 2) at 630 nm wavelength. For 24
hours reading, wounded AEC monolayers were treated
with SF-MSC CM or 2% FBS supplemented MSC-CM or
SF-CCD 8Lu CM or 0.2% FBS supplemented CCD-8Lu
CM for 24 hours in the incubator. For negative and posi-
tive control, cells were treated with SF-or 0.2% FBS
Figure 1 Characterisation of hMSC and alveolar A549 cells. (A) Human type II alveolar epithelial cell line, A549 cells were positive for type II
AEC marker proSP-C. Phase contrast image is taken from an independent field to the proSP-C and proSP-C/DAPI field. (B) hMSCs isolated from
human bone marrow aspirates were positive for mesenchymal stem cell markers CD44, STRO-1, CD90 and CD146; and negative for
haematopoietic markers CD14 and CD19. (C) hMSC tri-lineage differentiation: osteogenesis, adipogenesis and chondrogenesis were confirmed by
cytochemical/immunocytochemistry staining with Alizarin Red/anti-Osteocalcin, Oil Red O/anti-FABP-4 and Alcian Blue/anti-Aggrecan respectively.
Scale bars, 100 μm.
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Figure 2 hMSC paracrine stimulation of AEC and SAEC wound repair in vitro. (A) AEC (grey bars) and SAEC (black bars) wound repair after
24 hours with SF-MSC CMDMEM and SF-MSC CMSABM respectively. Negative controls indicates SF-DMEM for AEC and SF-SABM basal media for
SAEC. Positive control represent wound repair with 10% FBS supplemented DMEM for AEC and SAGM for SAEC (AEC, n = 8; SAEC, n = 12;
***p < 0.001). (B) AEC wound repair after 24 hours with hMSC conditioned media and DMEM supplemented with different concentration of FBS
(n = 8; ***p < 0.001 vs DMEM). (C) Inverted light microscopic images of SAEC wound repair. Negative and positive controls indicate serum-free
SABM and complete SAGM, respectively. (D) Inverted light microscopic images of AEC wound repair. (E) Representative inverted light microscopic
images of AEC wound margins after 24 hours in SF-DMEM, SF-MSC CMDMEM and 10% FBS supplemented DMEM. Numbers of migrating AECs
were observed at the wound margins of SF-MSC CM (arrows) and DMEM + 10% FBS treated samples. (F) The internuclear distances of AECs at
wound margins after 24 hours; SF-MSC CMDMEM (grey bar), DMEM + 10% FBS (open bar), and SF-DMEM (black bar) (n = 6; ***p < 0.001 vs SF-
DMEM). (G) AEC proliferation (by MTT assay) after 24 hours of wounding treated with SF (black bars) and 0.2% FBS supplemented (grey bars)
DMEM and MSC-CM, and 10% FBS supplemented DMEM (open bar). (n = 4; ***p < 0.001). Data presented as mean ± SD; ns = not significant. Scale
bars 200 μm (C and D) and 100 μm (E).
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Figure 3 CCD-8Lu paracrine stimulation of AEC wound repair in vitro. (A) AEC wound repair after 24 hours with SF (black bar) and 0.2% FBS
supplemented (grey bar) CCD-8Lu CM. Negative controls represent wound repair with SF-DMEM (black bar) and 0.2% FBS supplemented DMEM
(grey bar). Positive control represent wound repair with 10% FBS supplemented DMEM (black bars = positive control for SF-media treated
samples; grey bars = positive control for 0.2% FBS supplemented treated samples). (n = 12; ***p < 0.001). (B) AEC proliferation (by MTT assay) after
24 hours of wounding treated with SF (black bars) and 0.2% FBS supplemented CCD-8Lu CM (grey bars). Negative controls represent AEC
proliferation after 24 hours with SF or 0.2% FBS supplemented DMEM and positive control represents AEC proliferation with 10% FBS
supplemented DMEM (open bar). (n = 4; ***p < 0.001). (C) Representative inverted light microscopic images of AEC wound repair. Negative
control = SF-DMEM, Positive control = 10% FBS supplemented DMEM. Data presented as mean ± SD. ns = not significant. Scale bar, 200 μm.
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DMEM respectively. After 24 hours of incubation, media
was discarded and MTT was performed as above. Tripli-
cate was done for each sample. Data was presented as per-
centage increase of optical density (OD) reflecting degree
of cell proliferation after 24 hours (Figure 2G, 3B).
AEC-MSC direct-contact co-culture assay
Direct-contact co-culture wound repair experiment was
performed following a previously published methodology
with slight modification [29]. Briefly, 105 DiI-labeled AEC
and 105 DiO-labeled hMSCs (Vybrant™ Multicolor Cell
Labeling Kit, Invitrogen) were grown to confluency in
complete culture media on the contra-lateral surfaces of 3
μm porous PET (polyethylene terephthalate) membranes
of the 24-well plate format transwell over 24 hours (BD
Bioscience) (Figure 4A). Linear wounds were made on
AEC monolayers as described above. Wounded cells were
then cultured in SF-DMEM for 24 hours (Figure 4B).
Prior to imaging hMSCs were removed carefully with a
cotton swab from the undersurface of the PET membrane.Cells of upper surface of PET membrane were then fixed
with 4% paraformaldehyde. Images were acquired with a
laser scanning confocal microscope (Olympus Fluoview)
at both 0 and 24 hours. Wound gap measurement and
wound repair analysis were performed as described above
(Figure 4C).
For assessment of hMSC migration to AEC wound
sites in AEC-MSC direct-contact co-culture DiO-labelled
hMSCs were counted at the AEC wound gaps and their
juxta-wound monolayers at 0 and after 24 hours of
wounding (Figure 4D). Confocal Z-scanning was per-
formed to confirm the migration (Figure 4B, vertical
and horizontal bars). A minimum of three fields were
counted per sample.
Secretome analysis by mass spectrometry
For identification of secretory proteins in MSC-CM,
serum-free and 0.2% FBS supplemented MSC conditioned
media was concentrated (Amicon Centriplus Centrifugal
Filter Device, 3 kDa MW cut off; Millipore). Samples were
reduced and alkylated with 1 μL of 1M DTT for 1 hour at
Figure 4 hMSC migrate to the AEC wound sites and close wound gaps. (A) Schematic diagram showing two-cell direct contact co-culture
wound repair model using 3 μm porous transwell system. (B) Laser scanning confocal micrographs of AEC-MSC direct contact co-culture wound
repair model at 0 and 24 hours. Red cells are DiI labelled AECs and green cells are DiO labelled hMSCs. Horizontal panels are the Z-slicing
through the wound gaps and the vertical panels are Z-slicing through the corresponding juxta-wound monolayers. Appearance of green signals
in the same plane of red signals in the in the Z-slice after 24 hours confirms hMSC migration to the AEC wound site. (C) AEC-MSC direct contact
co-culture vs. negative and positive controls. Black and grey bars indicate AEC and hMSC contribution to repair, respectively. Negative control
represents AEC wound repair in SF-DMEM in mono-culture setting on upper surface of transwell PET membrane. Positive control represents AEC
wound repair in 10% FBS supplemented DMEM in mono-culture setting on upper surface of transwell PET membrane. (n = 6; ***p < 0.001).
(D) hMSC migration in a direct contact co-culture wound repair system (n = 13; ***p < 0.001). Data presented as mean ± SD. Scale bar, 150 μm.
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at room temperature in the dark followed by overnight di-
gestion with porcine sequencing grade trypsin (2 μg per
sample, Promega). The digested samples were then se-
parated by liquid chromatography. Peptides were eluted
for 40 minutes over a 2%-50% MeCN gradient, followed
by further elution for 10 minutes at 90% MeCN. Samples
were spotted onto a MALDI plate and analyzed in both
MS and MS/MS mode on a 4800 MALDI TOF/TOF (Ap-
plied Biosystems). Data was searched against the NCBI nr
Human database. Proteins that were matched with >95%
total ion score C.I% and more than 2 peptides were
considered as significant. MSC-CM from three independ-
ent donors were evaluated to identify common proteins.
Testing of proteins on AEC and SAEC wound repair
Plasma Fibronectin (Sigma), Lumican, Periostin and
IGFBP-7 (R & D System) recombinant human proteins
were assessed in the above described AEC and SAEC
in vitro wound repair system. Linear wounds were made
on AEC confluent monolayers and treated with the
above described proteins in soluble form in SF-DMEM
or in 0.2% FBS supplemented DMEM at different
concentrations (1 pg/ml to 100 μg/ml). SAEC woundswere treated with above mentioned proteins in SF-SABM
for 24 hours. For negative control (NC), wounded AEC
were treated with SF-DMEM or 0.2% FBS supplemented
DMEM and SAEC were treated with supplement-free
basal SABM for 24 hours. For positive control (PC),
wounded AEC were treated with 10% FBS supplemented
DMEM and SAEC were treated with complete SAGM.
Individual positive controls were run for SF and 0.2% FBS
supplemented AEC samples. PC were run side-by-side
each NC to ascertain the wound repair system was wor-
king properly. Percentage of wound repair after 24 hours
was calculated as described previously (Figure 5).
Collagen drop cell migration assay
To evaluate the effect of above identified proteins on AEC
migration as substrate components, we developed a cell
migration assay tool where 5 × 104 AECs were resus-
pended in 10 μl of 1 mg/ml concentration of rat tail colla-
gen I (BD Bioscience) in 0.2% FBS supplemented DMEM.
The cell/collagen solution was dropped on different con-
centration of Fibronectin or Lumican or Periostin coated
24-well plates. Well-plates were coated with proteins by
adding 500 μl of different concentrations of proteins and
incubating them at 4°C over night. After incubation,
Figure 5 (See legend on next page.)
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Figure 5 AEC and SAEC wound repair stimulation by individual hMSC paracrine factors. (A) Recombinant human plasma Fibronectin did
not enhance AEC wound in serum-free condition (open bars) but required 0.2% FBS supplementation (black bars) (n = 6; **p < 0.01, ***p < 0.001)
(B) Recombinant human plasma Fibronectin significantly increased SAEC wound repair at 100 ng/ml concentration in SF-SABM (grey bar) vs.
negative control (NC) (black bar) (n = 6; *p < 0.05). (C) Recombinant human Lumican did not enhance AEC wound in serum-free condition (open
bars) but required 0.2% FBS supplementation (black bars) (n = 9; **p < 0.01, ***p < 0.001). (D) Recombinant human Lumican significantly increased
SAEC wound repair (n = 6; **p < 0.01, ***p < 0.001). (E) Recombinant human Periostin enhanced AEC wound repair (n = 10, **p < 0.01, ***p < 0.001;
$p < 0.001 vs corresponding serum-free NC). (F) Periostin increased SAEC wound repair at 1 μg/ml in SF-SABM (n = 6; *p < 0.05). (G) Human
recombinant IGFBP-7 did not stimulate AEC wound repair in serum-free (open bars) or 0.2% FBS supplemented conditions (black bars) (n = 9;
*p < 0.001 vs 0.2% FBS supplemented NC, $p < 0.001 vs serum-free NC). (H) Recombinant human IGFBP-7 significantly stimulated SAEC wound
repair (n = 6; **p < 0.01, ***p < 0.001). NC (negative control) represents wound repair with DMEM for AEC and serum-free SABM for SAEC. PC
(positive control) represents wound repair with 10% FBS supplemented DMEM for AEC and complete SAGM for SAEC. Data presented as mean ±
SD. ns = not significant. Scale bar, 200 μm.
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ing the collagen drop. Acidity of collagen was neutralised
using 1M NaOH buffer. A single drop (10 μl) was placed
at the centre of each well and incubated for 30 minutes in
the humidified incubator at 37°C allowing the drops to
form into gel. Following gel formation, 600 μL of 20% FBS
supplemented DMEM was added to each well to provide a
chemoattractant-bias for the promotion of cell migration
out of the gel barrier (Figure 6A). After 24 hours migratory
cells were quantified microscopically. The radius of each
drop was measured by Image J software and the circumfer-
ence of each drop was calculated. Results are expressed as
mean migration through per millimeter of circumference
of collagen-drop barrier (Figure 6B, 6C).
Statistical analysis
The significance of difference between groups was
determined by one-way ANOVA with Post-hoc Tukey’s
Multiple Comparison analysis. A ‘p’ value less than 0.05
was considered to indicate statistical significant. Data are
presented as mean ± standard deviation (SD). All statis-
tical analysis was performed using GraphPad Prism ver-
sion 5.00 software for Windows (GraphPad Software, San
Diego, California, USA).
Results
hMSC secretome stimulates alveolar epithelial cell wound
repair in a serum-dependant manner
To investigate the role of the hMSC secretome on AEC
and SAEC wound repair, human MSC-derived serum-free
conditioned media was tested on proSurfactant protein-C
(proSP-C) expressing human type II AEC line A549
(AEC) (Figure 1A) and primary human SAEC utilising an
established in vitro scratch wound repair model [27]. A
characteristic of idiopathic pulmonary fibrosis is aberrant
repair processes in wounded alveolar epithelium resulting
in denuded epithelium [13]. The source of these wounds
remains unknown but disrupted repair of the alveolar
epithelium is the underlying principle. The use of the
scratch wound repair model replicates the wounds, andthrough the controlled experimentation we describe,
allows replication of the inability to repair and a platform
to test novel factors in repair stimulation. hMSC were
isolated from bone marrow aspirates according to previ-
ously described methodology [25,26] and immunophe-
notype (CD44+, CD90+, CD146+, STRO-1+, CD14-, and
CD19-) (Figure 1B) was confirmed prior to experimental
use. The multipotency of hMSC was confirmed by dif-
ferentiation into osteogenesis, adipogenesis and chon-
drogenesis lineages, confirmed by use of traditional
cytological and immunological studies using Alizarin
Red/Osteocalcin, Oil Red O/FABP-4 and Alcian Blue/
Aggrecan respectively (Figure 1C). hMSC serum-free
conditioned media (SF-MSC CMDMEM) did not show
any stimulatory effect on AEC wound repair after 24
hours (36.0 ± 9.8% SF-MSC CMDMEM vs. 34.6 ± 6.6% SF-
DMEM (negative control)) whereas SAEC wound repair
was increased with SF-MSC CMSABM (93.5 ± 7.6%
SF-MSC CMSABM vs. 66.8 ± 6.6% SF-SABM (negative
control); p < 0.001) (Figure 2A, 2C). Surprisingly, supple-
mentation of SF-MSC CMDMEM with trace amounts of
FBS improved the rate of AEC wound repair stimulation
when compared with corresponding DMEM controls
supplemented with same amounts of FBS (Figure 2B).
Maximal effect was observed with the addition of 0.2%
FBS in SF-MSC CMDMEM over its corresponding con-
trol (0.2% FBS supplemented DMEM) (66.3 ± 7.4% vs.
35.7 ± 9.5%; p < 0.001) (Figures 2B and 2D). The correl-
ation between wound repair rate and increase in FBS
addition was poor, though consistent, when FBS
concentrations of <1% were examined. This was noted
for both SF-MSC CMDMEM and DMEM (Figure 2B).
SF-MSC CMDMEM without additional FBS supple-
mentation did not increase the AEC wound repair rate.
However, when exposed to SF-MSC CMDMEM for 24
hours, isolated AECs migrated from their wound mar-
gins towards wound gaps with an accompanying migra-
tory morphology (Figure 2E). Inter-nuclear distances, a
measure of migration [27,30], in SF-MSC CMDMEM
treated AEC were significantly higher than that observed
Figure 6 Fibronectin and Lumican but not Periostin stimulate AEC migration as substrate components. (A) Schematic diagram shows
collagen drop cell migration assay. (B) Fibronectin and Lumican coating at various concentration stimulate AEC migration (Fibronectin, n = 3;
Lumican, n = 6). Periostin coating did not stimulate AEC migration (n = 6). (C) Representative images of AECs migration across the collagen-drop
barrier. Data presented as mean ± SD. ***p < 0.001. Scale bar, 250 μm.
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30.6 ± 3.0 μm; p < 0.001) (Figure 2F). Next, we investigated
the influences of 0.2% FBS supplementation with SF-MSC
CMDMEM or SF-DMEM on AEC proliferation during
in vitro wound repair. The MTT assay, an established
method for determination of cell proliferation, demons-
trated that supplementation of SF-MSC CMDMEM or SF-
DMEM with 0.2% FBS did not increase AEC proliferation
after 24 hours of wound repair; whereas, supplementation
of 10% FBS with DMEM significantly increased AEC
proliferation in comparison to both SF-DMEM and SF-
MSC CMDMEM (p < 0.001) (Figure 2G). Taken together,
serum-free MSC conditioned media alone can stimulate
migratory behaviour of AEC during attempted wound re-
pair but does not induce AEC wound repair without sup-
plementation of additional trace levels of serum. However,
SAEC wound repair required SF-MSC CMSABM only.
These findings demonstrate a phenotype-dependant and
anatomical compartment-specific diverse paracrine re-
sponse to hMSC secretome on distal airway and AEC
wound repair where, at least for the AEC, the reparative
process was accomplished by stimulation of cell migra-
tion. On the contrary, serum-free or 0.2% FBS supple-
mented conditioned media obtained from normal
human lung fibroblasts CCD-8Lu (CCD-8Lu CM) nei-
ther enhanced AEC wound repair (Figure 3A, 3C) nor
stimulated AEC cell proliferation (Figure 3B). This ob-
servation suggests a distinct influence of hMSC and
normal human lung fibroblasts on alveolar epithelial
wound repair.
hMSC migrate into wounded AEC layers in response to
injury
hMSC migration to the site of injury is proposed as an
important element of AEC wound repair and regener-
ation in animal models of pulmonary fibrosis [17]. To
investigate the migratory properties of hMSC we de-
veloped a two-cell co-culture 3D wound repair model
(Figure 4A). In response to AEC injury hMSCs migrated
into the AEC wound and completely closed the wound
gap (Figure 4B and 4C). AEC wound repair was signifi-
cantly lower in both the negative and positive control than
in the AEC-MSC direct contact co-culture (28.0 ± 6.5%
(negative control, AEC upper PET membrane surface
mono-culture in SF-DMEM), 72.0 ± 6.9% (positive con-
trol, AEC upper PET membrane surface mono-culture
in 10% FBS DMEM) and 100% (AEC-MSC direct-contact
in SF-DMEM) respectively; p < 0.001 vs AEC-MSC direct
contact) (Figure 4C). Cell migration assessment demons-
trated a 5-fold higher hMSC migration into wound gaps
over the juxta-wound monolayers after 24 hours of direct
contact co-culture (mean values 308.3 ± 13.9 (wound gap)
vs. 66.0 ± 13.4 (juxta-woundmargin); p < 0.001) (Figure 4D).
In the absence of AEC, hMSC did not migrate to theopposite surface of the porous transwell membrane (data
not shown).
Proteins detected in MSC conditioned media show
differential wound repair potential
hMSC conditioned media enhanced AEC migration and
wound repair (with trace FBS supplementation). We
hypothesised that candidate molecules within the hMSC
secretome could enhance alveolar epithelial cell wound re-
pair. To test this hypothesis, we first evaluated the compos-
ition of the SF-MSC CMDMEM secretome from hMSC
isolated from three donor independent marrow samples
using LC-MS/MS mass spectrometry (Table 1). Our pri-
mary target cell type was AEC; however, we replicated
equivalent experiments on SAEC to compare and contrast
the wound repair responses to the paracrine stimuli of
commonly identified hMSC-secreted candidate proteins.
Fibronectin and Lumican displayed no effect on AEC
wound repair rate when added to serum-free medium;
however, when supplemented with 0.2% FBS they signifi-
cantly increased AEC wound repair (Figure 5A and 5C).
Fibronectin-induced wound repair was maximal at a con-
centration of 100 ng/ml when compared to the cor-
responding control medium (50.8 ± 6.7% vs. 33.8 ± 6.3%
(0.2% FBS supplemented DMEM); p < 0.001) (Figure 5A).
Lumican displayed maximal wound repair effects at a 1
ng/ml concentration (58.7 ± 8.9% vs. 29.8 ± 3.5% (0.2% FBS
supplemented DMEM)); p < 0.001) (Figure 5C). In con-
trast, Fibronectin and Lumican significantly increased
SAEC wound repair without an additional serum supple-
mentation requirement (Figure 5B and 5D). Fibronectin
displayed a maximal wound repair effect on SAEC with a
100 ng/ml concentration (73.0 ± 12.9% vs. 49.1 ± 8.5%
(SABM); p < 0.05) (Figure 5B); whereas, Lumican displayed
significant wound repair effect at a concentration of 100
ng/ml (92.1 ± 6.6% vs. 53.8 ± 12.4% (SABM); p < 0.001)
(Figure 5D). Unlike Fibronectin and Lumican, Periostin
significantly enhanced AEC wound repair without any
additional supplementation where a maximal effect was
observed with a 100 ng/ml concentration in serum-free
medium (50.0 ± 4.5% vs. 28.9 ± 2.4% (SF-DMEM); p < 0.01)
(Figure 5E). Periostin also enhanced SAEC wound repair
in serum-free basal medium (90.1 ± 5.2% vs. 61.8 ± 15.9%
(SABM); p < 0.05) (Figure 5F). On the other hand
IGFBP-7 (Insulin-like growth factor binding protein-7)
showed no significant effect on AEC wound repair
(Figure 5G); whereas, SAEC wound repair was signifi-
cantly stimulated by all tested concentrations of IGFBP-7
in serum-free basal media where a maximum effect was
observed with 100 ng/ml concentration (95.3 ± 3.5% vs.
53.3 ± 13.3% (SABM); p < 0.001) (Figure 5H). Gelatinase
A (MMP2) had no discernable effect on either wound
repair rate or migration in AEC wound repair (data not
shown).
Table 1 Protein components of SF-MSC CM detected by LC-MS/MS mass spectrometry
Protein name Accession number Average Peptide count
Fibronectin 1, isoform CRA_j gi|119590945 39.0
Collagen alpha-2(I) chain gi|124056488 30.0
Collagen alpha 1 chain precursor variant gi|62088774 23.5
Pro alpha 1(I) collagen gi|186893270 23.5
Alpha 1 (I) chain propeptide gi|180392 21.3
Collagen, type VI, alpha 1 precursor gi|87196339 11.0
Precursor polypeptide (AA −31 to 1139) gi|37465 7.5
Actin, gamma 1 propeptide gi|4501887 7.0
Gelatinase A gi|5822007 6.7
Keratin 1 gi|7331218 6.5
Tumor necrosis factor gi|339992 6.3
Osteoblast specific factor 2 (Periostin) gi|393319 6.0
Chain A, Crystal Structure Of The Thrombospondin-1 gi|88191917 5.5
Biglycan gi|179433 4.7
Lumican gi|642534 4.7
Collagen alpha 1(V) chain precursor gi|219510 4.5
Insulin-like growth factor binding protein 7, isoform CRA_a gi|119625925 4.5
CALU gi|49456627 4.0
Thrombospondin 2 precursor gi|40317628 4.0
Fructose-bisphosphate aldolase A gi|4557305 3.5
Heparan sulfate proteoglycan gi|184427 3.5
Pigment epithelium-derived factor gi|1144299 3.5
Profilin Binds Proline gi|5822002 3.0
Protein disulfide isomerase gi|860986 3.0
Versican isoform 3 precursor gi|255918077 3.0
Decorin gi|181519 2.7
The Antigenic Identity Of Peptide(Slash)mhc Complexes gi|442989 2.5
COL1A1 and PDGFB fusion transcript gi|3288487 2.5
Peptidylprolyl isomerase A gi|10863927 2.5
Fibrillin gi|306746 2.0
Similar to cardiac leiomodin gi|51095092 2.0
Solution Structure Of Calcium-Calmodulin N-Terminal Domain gi|16974825 1.7
Myosin, light chain 6, alkali, smooth muscle and non-muscle isoform 1 gi|17986258 1.5
Protein disulfide-isomerase A3 gi|729433 1.5
Insulin-like growth factor binding protein 6 gi|183894 1.0
SF-MSC CM preparation was as described in Materials and Methods. Proteins selected for investigations in wound repair and migration are indicated in bold.
Accession numbers are derived from MS/MS data searches against non redundant Human NCBI Protein Database. Average peptide count from 3 biologically
independent replicates of hMSC secretome profiles.
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migration as substrate components
Fibronectin, Lumican and Periostin induced AEC wound
repair when delivered as a culture medium supplement.
As these proteins are abundant within the ECM, we
hypothesised that these proteins could influence AEC
migration as substrate components. Immediate relevance
to fibrotic lung disease is evidenced by the abrogation of
effective AEC migration over denuded alveolar epithelium.
To test this hypothesis, we developed a ‘collagen drop’cell migration assay where an aggregated population of
AECs were resuspended in a drop of collagen which was
‘dropped’ onto a surface coated with Fibronectin, Lumican,
or Periostin. To provide an additional ‘positive’ bias to
AEC migration the collagen drop contained 0.2% FBS
whereas the external serum concentration was 20%
(Figure 6A). Optimal cell migration was observed on either
Fibronectin or Lumican coated surfaces at a concentration
of 10 ng/ml (Fibronectin 27.7 ± 11.1 cells/mm vs. 6.7 ± 1.5
cells/mm (uncoated surface), p < 0.001; Lumican 30.7 ± 6.8
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0.001) (Figure 6B, 6C). On the other hand, Periostin did
not stimulate AEC migration (Figure 6B, 6C). Taken toge-
ther this indicates that Fibronectin and Lumican stimu-
lated AEC wound repair as both soluble factors and as a
substrate component whereas Periostin stimulated AEC
wound repair as a soluble factor only.
Discussion
Human mesenchymal stem cells (hMSC) are in current
clinical trials for incurable diseases including osteogen-
esis imperfecta, graft-versus-host disease, chronic ische-
mic heart disease, and chronic obstructive pulmonary
disease (www.clinicaltrials.gov) and are the focus of
many other clinical applications. Studies on animal pul-
monary fibrosis models demonstrate that intravenous
and endotracheal administration of MSCs attenuate lung
injury and fibrosis suggesting a potential clinical applica-
tion of MSCs for the treatment of IPF [16,17,31]. How-
ever, the mechanism of MSC-mediated amelioration of
pulmonary fibrosis is not clear and an active participa-
tion of MSCs through differentiation into AEC and lung
regeneration is under debate [16,32]. Bleomycin-induced
mouse lung fibrosis models have demonstrated an MSC
stimulated reduction in pulmonary fibrosis via inhibition
of pro-fibrotic cytokines TNF-α and IL-1 through a
paracrine mechanism [33]. Furthermore, rat models of
pulmonary emphysema demonstrated that MSCs reduce
AEC apoptosis through paracrine mechanism via up-
regulation of anti-apoptotic Bcl-2 gene [34]. Here we
demonstrate that in response to injury, hMSC display
site-specific migration into AEC wounds; this observa-
tion has also been noted by others in animal lung injury
models [16,17]. Coupled to this hMSC migration, we
also demonstrate that in response to SF-MSC CM, AEC
and SAEC migration and wound repair occur with dis-
tinct trace serum augmentation requirements. We also
provide evidence supporting specific hMSC-secreted
paracrine components for effective alveolar and small
airway epithelial wound repair.
hMSC secret a myriad of proteins that include growth
factors, cytokines and ECM proteins [19,20]. Many of
these secretory proteins are biologically active with anti-
inflammatory, anti-fibrotic and immunomodulatory func-
tions [21,22]. Previous and current studies are mostly fo-
cused on evaluation of MSC-secreted growth factors and
their effects on tissue repair. Here, in line with others, our
mass spectrometry-mediated hMSC secretome analyses
indicate the presence of a high abundance of ECM/
matricellular protein components with diverse biological
activities on wound healing and tissue repair [20,23].
Fibronectin (a multifunctional glycoprotein), Lumican
(collagen-binding keratin sulfate proteoglycan), Periostin
(matricellular N-glycoprotein), and IGFBP-7 (IGF-I, -IIlow affinity binding protein) were identified as major
components of SF-MSC CM through high peptide counts
and ion score confidence intervals (Table 1). Data sup-
portive of a role for these factors in alveolar wound repair
is relatively scarce though implied in previous studies.
Fibronectin upregulation is implicated in abdominal wall,
corneal, and skin in vivo and ex vivo wound repair and
migration where values ranging from 100 ng/ml to 60 μg/
ml of Fibronectin have been evaluated [35-39]. In vitro
models including corneal epithelial cells, corneal fibro-
blasts, keratinocyte, dermal fibroblast, nasal airway epithe-
lial cells, gingival fibroblast, and SAEC have further
demonstrated that fibronectin stimulated wound repair
and cell migration as either soluble factor or substrate
component frequently through integrin signaling activa-
tion [40-45].
Lumican, a small leucine-rich proteoglycan (SLRP) fam-
ily member, is a major component of the proteoglycan-
based ECM. Lumican displays a heterogeneous, diffuse,
staining profile in the alveolar walls and peripheral regions
of adult human lung and its sub-epithelial deposition is
implicated in airway remodeling and counteracting the se-
verity of asthma [46,47]. In vivo and ex vivo studies indi-
cate that Lumican is essential for corneal epithelial cell,
skin, and oral mucosa wound repair and promotion of
chemotactic migration [48-51]. In vitro migration and
wound healing of corneal epithelial cells was also induced
by Lumican [52,53]. Circulating plasma and cellular
Fibronectin concentrations (300 μg/ml and 2.46 μg/ml, re-
spectively) are substantially in excess of those required to
induce wound repair and migration in our, and previously
described (see above), in vitro models whereas physio-
logical levels of Lumican are yet to be defined [54]. In sup-
port and extension of these previous reports we have now
demonstrated that both Fibronectin and Lumican faci-
litated AEC and SAEC wound repair as soluble factors
(with trace serum supplementation for AEC only) and mi-
gration of AEC as a substrate component.
Periostin (or OSF-2, Osteoblast Specific Factor-2) is a
matricellular protein with a poorly defined role in wound
repair and a physiological serum level of approximately 39
ng/ml [55,56]. In vivo studies revealed an association with
fracture healing, wound-derived blood vessels, acute myo-
cardial infarction response, skin wounds, and ligament
repair [57-62]. In addition to those above low levels of
Periostin expression are common in normal lung while
high levels of Periostin are detected in IPF lungs and pa-
tient serum although the role of this protein in the patho-
genesis of lung fibrosis has not been clarified [56]. A
relationship between Periostin and wound repair across
multiple tissues is immediately apparent though little is
known, at this time, of mechanism of action. A solitary re-
port describes exogenous overexpression of Periostin in
A549 cells, as used in our study, which enhanced both
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have herein reported that Periostin has a role in AEC and
SAEC wound repair and migration as a soluble factor and
identified a putative hMSC source of wound associated
Periostin.
IGFBP-7 (also known as IGFBP-rP1) is an IGFBP-related
protein (IGFBP-rPs) superfamily member. IGFBP-rPs have
less binding affinity to IGF (insulin growth factor) and are
involved in diverse biological activities in an IGF-
independent manner [64]. IGFBP-rP2 (CTGF (connective
tissue growth factor)), another IGFBP-rP family member,
plays a critical role during fibrogenesis in IPF [65,66]. How-
ever, the role of IGFBP-7, which has a normal serum con-
centration of 33 ng/ml [67], in pulmonary fibrosis is
unknown. IGFBP-7 is up-regulated in the fibrotic regions
of IPF lung tissue as well as in isolated IPF fibroblasts
though absent from controls [68]. Here we have de-
monstrated that recombinant human IGFBP-7 significantly
increased human primary SAEC wound repair when ap-
plied in serum-free basal media, whereas AEC were non-
responsive to this protein. The mechanism behind these
divergent responses remains to be clarified. The develop-
ment of transferable and accessible primary human AEC
cultures (which replicate in vivo characteristics; i.e. mono-
layer formation) will be necessary before clarification can
be achieved. However at this time we cannot preclude the
possibility that the distinct response is due tissue source or
phenotypic background of the AEC and SAEC used in this
study. However this distinction in response provides strong
support for broad therapeutic applicability across multiple
clinical applications for the hMSC secretome. Charac-
terization of these cell-specific responses will underpin the
continuing development of the stem cell-driven regenera-
tive medicine industry.
The protein composition of ECM is variable, tissue spe-
cific, and provides essential scaffold and biochemical
signals required for cell growth, tissue homeostasis, devel-
opment and wound repair [55,69]. Our in vitro AEC
wound repair data encouraged us to investigate the sub-
strate roles of Fibronectin, Lumican and Periostin on AEC
migration. The in vitro scratch wound repair system is not
suitable to test the effectiveness of individual substrate
components as the wounding process would disrupt the
protein coating. We developed a novel ‘collagen drop’ cell
migration assay to evaluate individual substrate component
capacity to support or inhibit migration. Normal basement
membrane architecture provides a favourable substrate for
AEC migration whereas disrupted alveolar basement mem-
brane and aberrant ECM remodeling play a crucial role in
the abrogation of alveolar re-epithelialisation in pulmonary
fibrosis [13]. Data from our ‘collagen drop’ cell migration
assay has identified that both Fibronectin and Lumican are
supportive of cell migration as substrate component. From
consideration of the data obtained from wound repair andcollagen drop assays we suggest a putative dual role (as
topical and substrate components) of Fibronectin and
Lumican, and a topical role of Periostin on alveolar epithe-
lial cell migration and wound repair. Fibronectin, Lumican
and Periostin have diverse biological effects on various cell
types depending on their interactions with different recep-
tor families, such as integrins, receptor tyrosine kinases
(RTKs) and IGF-receptor [69-73]. It can be speculated that
an individual candidate protein may stimulate different
receptors depending on the mode of application with the
potential to trigger different outcomes. Here our two dif-
ferent assay systems illustrated the effects of Periostin on
AEC migration operated in an administration-dependent
fashion. Further elucidation of hMSC secretory proteins
and their interactions with target receptors in alveolar epi-
thelial wound repair will provide a clear understanding in
hMSC-mediated alveolar injury repair and regeneration.
Conclusion
These data provide insight into potential hMSC paracrine
influences on epithelial wound repair during alveolar in-
jury repair. Aberrant alveolar re-epithelialisation is be-
lieved to be one of the major contributing factors for
uncontrolled fibrogenesis in IPF [13]. Therefore, stimula-
tion of re-epithelialisation within the alveolar regions could
be a potential active vector for alleviation of the pro-
fibrogenic processes as a curative therapeutic measure for
IPF. Previous animal model-based studies demonstrated
that MSC-paracrine factors attenuate pulmonary fibrosis
through modulation of inflammation, suppression of
fibrogenesis and stimulation of angiogenesis [19,20,31,33].
Here, we have demonstrated the efficacious influence of
the hMSC secretome in the modulation of alveolar and
small airway epithelial cell dynamics resulting in stimu-
lation of wound repair. In-depth understanding of the
humoral mechanisms of hMSCs in epithelial wound repair
and regeneration will provide extended therapeutic options
for clinical application of hMSC or their secretory products
for fibrotic lung diseases, such as IPF.
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